|Articles|June 15, 2003

BioPharm International

  • BioPharm International-06-01-2003
  • Volume 16
  • Issue 6

SOX in the Boardroom: What the Sarbanes?Oxley Act Means to You

Author(s)Penny Cass

by Penny Cass, BioPharm International Stay current on the changes in corporate governance regulations ? whether your company is public or private, in the United States or elsewhere. As a capital-intensive industry, many of our third-party associations are going to require that biopharmaceutical companies comply with the new regulations to receive financing. The trend to regulate corporate governance activities hasn't ended ? more rules promulgated by more government entities should be anticipated.

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.